Abivax S.A. (ABVX) Revenue History
Annual and quarterly revenue from 2014 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
ABVX Revenue Analysis (2014–2024)
As of March 1, 2026, Abivax S.A. (ABVX) generated trailing twelve-month (TTM) revenue of $15.1 million, reflecting significant decline in growth of -40.6% year-over-year. The most recent quarter (Q2 2025) recorded $2.0 million in revenue, down 72.7% sequentially.
Looking at the longer-term picture, ABVX's 5-year compound annual growth rate (CAGR) stands at +457.7%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $10.8 million in 2024, representing a new all-time high.
When compared to Healthcare sector peers including ARGX (+335.2% YoY), CANF (-16.0% YoY), and KYMR (-16.7% YoY), ABVX has underperformed the peer group in terms of revenue growth. Compare ABVX vs ARGX →
Peer Comparison
Compare ABVX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ABVXCurrent | $15M | -40.6% | +457.7% | -1602.9% | |
| ARGX | $2.2B | +335.2% | +94.6% | -1.0% | |
| CANF | $674,000 | -16.0% | -19.8% | -1206.2% | |
| KYMR | $39M | -16.7% | +2.9% | -891.3% | |
| TGTX | $329M | +31.0% | +364.6% | 12.7% | |
| KNSA | $678M | +60.1% | - | 11.4% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $10.8M | +133.5% | $10.8M | 100.0% | $-172,984,000 | -1602.9% |
| 2023 | $4.6M | +0.8% | $4.6M | 99.0% | $-127,376,000 | -2756.5% |
| 2022 | $4.6M | +12286.5% | $4.5M | 97.6% | $-64,836,000 | -1414.7% |
| 2021 | $37K | -41.3% | $-119,000 | -321.6% | $-41,400,000 | -111891.9% |
| 2020 | $63K | +3050.0% | $-33,769,000 | -53601.6% | $-38,008,000 | -60330.2% |
| 2019 | $2K | -88.9% | $-28,186,000 | -1409300.0% | $-33,296,000 | -1664800.0% |
| 2018 | $18K | +80.0% | $-50,000 | -277.8% | $-19,108,000 | -106155.6% |
| 2017 | $10K | -92.1% | $-6,000 | -60.0% | $-14,150,000 | -141500.0% |
| 2016 | $127K | +202.4% | $-14,518,000 | -11431.5% | $-18,236,000 | -14359.1% |
| 2015 | $42K | +200.0% | $-303,000 | -721.4% | $-18,255,000 | -43464.3% |
See ABVX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABVX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ABVX vs AGIO
See how ABVX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ABVX's revenue growth accelerating or slowing?
ABVX revenue declined -40.6% year-over-year, contrasting with the 5-year CAGR of +457.7%. TTM revenue fell to $15M. This reverses the prior growth trend.
What is ABVX's long-term revenue growth rate?
Abivax S.A.'s 5-year revenue CAGR of +457.7% reflects the variable expansion pattern. Current YoY growth of -40.6% is below this long-term average.
How is ABVX's revenue distributed by segment?
ABVX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2024 are available for download. Segment mix reveals concentration and diversification trends.